We convened a panel of experts to identify the most significant methodological challenges in psychedelic trials and suggest how we may overcome (or embrace) them: with relevance within and beyond the psychedelics space. Part of our Year in Review series Since 2020, Hailey has built and overseen the strategy and process for the Investigator-Initiated Trials Program at MAPS Public Benefit…

Source

Previous articleHistorical Insights on the Psychedelic Renaissance
Next articleAustralia Recognises MDMA and Psilocybin as Medicines